The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Drug: vancomycin     Quarter: 2016Q3

Total Drug/Injury Combinations: 1,050     Number of Pages: 53

DRUGNAME PT EventCount
VANCOMYCIN Immunosuppressant drug level increased 1 view events
VANCOMYCIN Impaired work ability 1 view events
VANCOMYCIN Incorrect dose administered 1 view events
VANCOMYCIN Increased appetite 1 view events
VANCOMYCIN Inflammation 1 view events
VANCOMYCIN Infusion 1 view events
VANCOMYCIN Infusion related reaction 1 view events
VANCOMYCIN Infusion site erythema 1 view events
VANCOMYCIN International normalised ratio increased 1 view events
VANCOMYCIN Jaundice 1 view events
VANCOMYCIN Kidney infection 1 view events
VANCOMYCIN Lacrimation increased 1 view events
VANCOMYCIN Limb injury 1 view events
VANCOMYCIN Liver abscess 1 view events
VANCOMYCIN Localised infection 1 view events
VANCOMYCIN Lymphoedema 1 view events
Vancomycin Macular oedema 1 view events
VANCOMYCIN Mean cell haemoglobin increased 1 view events
VANCOMYCIN Mean cell volume increased 1 view events
VANCOMYCIN Mean platelet volume decreased 1 view events

Total Drug/Injury Combinations: 1,050     Number of Pages: 53

NOTE: EventCount numbers on this page include duplicate entries from event reports. (e.g. One event has DrugX entered twice, which equals 2 on this page.) The "view events" page treats these duplicates as single entries. (e.g. The 2 entries of DrugX for a single event are counted as 1 instance.)